Posts Tagged :

Oncology

COVID Jump-Starts Cancer Care at Home 150 150 Shields Health Solutions

COVID Jump-Starts Cancer Care at Home

As the COVID-19 pandemic spread across the country and hospitals reduced in-person visits to a bare minimum, health systems—such as Partners Healthcare, M Health Fairview and Northwestern—worked to ensure that…

Pandemic Management Strategies for Patients With Cancer at an Academic Medical Center 150 150 Shields Health Solutions

Pandemic Management Strategies for Patients With Cancer at an Academic Medical Center

By Martha Stutsky, PharmD, BCPS; and Osama Abdelghany, PharmD, MHA, BCOP Smilow Cancer Hospital at Yale New Haven Health System in Connecticut is 1 of 45 National Cancer Institute–designated comprehensive…

COVID-19 and the Impact on Oral Oncolytics: A Specialty Pharmacy Perspective 150 150 Shields Health Solutions

COVID-19 and the Impact on Oral Oncolytics: A Specialty Pharmacy Perspective

By Claudia S. Castro, PharmD, MS, BCOP, BCGP; and Amanda Manoogian, PharmD, BCOP The prevalence of individuals living with cancer continues to rise, largely because of an aging and growing…

COVID & Oncology – The Effects on Health System Specialty Pharmacies 1024 791 Shields Health Solutions

COVID & Oncology – The Effects on Health System Specialty Pharmacies

This blog was written by Excelera, a Shields company. Two months ago, our blog discussed the potential impacts and areas of concern for health system specialty pharmacies and COVID. However,…

Orlando Health Provides Patients with Improved Outcomes Through Increased Access to Innovative Oncology Treatments by Joining the Excelera Network 204 115 Shields Health Solutions

Orlando Health Provides Patients with Improved Outcomes Through Increased Access to Innovative Oncology Treatments by Joining the Excelera Network
Orlando Health is the first health system in Florida to partner with Excelera®, the company behind the Excelera Network, to further optimize its specialty pharmacy services and to provide patients with increased access to limited distribution drugs (LDDs), which include innovative oncology treatments.
Excelera® and Aptitude Health Partner to Improve Oncology Patient Outcomes Through Combined Clinical Knowledge and Education 204 115 Shields Health Solutions

Excelera® and Aptitude Health Partner to Improve Oncology Patient Outcomes Through Combined Clinical Knowledge and Education
Wolfe joins Excelera with significant experience in building strategic pharmaceutical manufacturer relationships for publicly traded and private organizations in the healthcare sector
New Combination Therapies for the Treatment of Chronic Lymphocytic Leukemia 150 150 Shields Health Solutions

New Combination Therapies for the Treatment of Chronic Lymphocytic Leukemia
Erin Kelley, PharmD, BCOP, and Jeff Engle, PharmD, MS, Fairview Health CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is the most common type of leukemia in adults and accounts for approximately 37% of new leukemia cases. An estimated 20,720 new cases of and 3930 deaths from CLL will occur in the United States in 2019.